甲磺酸伊喜替康
| 中文名称 | 甲磺酸伊喜替康 |
|---|---|
| 中文同义词 | 依沙替康甲磺酸盐;依喜替康甲磺酸盐;(1S,9S)-1-氨基-9-乙基-5-氟-9-羟基-4-甲基-2,3,9,10,13,15-六氢-1H,12H-苯并[DE]吡喃[3',4':6,7]氮茚并[1,2-B]喹啉-10,13-二酮甲磺酸盐;甲磺酸伊喜替康;甲磺酸依喜替康;依替喜康;甲磺酸依他替康;(1S,9S)-1-氨基-9-乙基-5-氟-9-羟基-4-甲基-2,3,12,15-四氢苯并[DE]吡喃并[3',4':6,7]吲哚并[1,2-B]喹啉-10,13(1H,9H)-二酮 甲磺酸盐 |
| 英文名称 | Exatecan mesylate |
| 英文同义词 | Exatecan mesilate;DX 8951f;Exatecan Meslate;169869-90-3 （free base）;DX 8951; DX 8951;169869-90-3 (FREE BASE);(1S,9S)-1-AMINO-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO[DE]PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLINE-10,13-DIONE MESYLATE;Exatecan (DX-8951) mesylate;DX8951F;DX 8951F;DX-8951F |
| CAS号 | 169869-90-3 |
| 分子式 | C25H26FN3O7S |
| 分子量 | 531.56 |
| EINECS号 | |
| 相关类别 | ADC毒素药物;细胞毒素;化学试剂 |
| Mol文件 | 169869-90-3.mol |
| 结构式 |  |
甲磺酸伊喜替康 性质
| 储存条件 | 4°C, protect from light, stored under nitrogen |
|---|---|
| 溶解度 | DMSO:7.41(最大浓度 mg/mL);13.94(最大浓度 mM) 水:0.0(最大浓度 mg/mL);0.19(最大浓度 mM) |
| 形态 | 固体 |
| 颜色 | 浅黄至黄绿色 |
| 稳定性 | 吸湿性 |
| InChIKey | BICYDYDJHSBMFS-OVCYJQQENA-N |
| SMILES | S(O)(=O)(=O)C.N[C@H]1CCC2C(C)=C(F)C=C3N=C4C5=CC6[C@@](C(=O)OCC=6C(=O)N5CC4=C1C3=2)(O)CC |&1:6,21,r| |
甲磺酸伊喜替康是一种DNA 拓扑异构酶 I (topoisomerase I) 抑制剂，IC50 值为 2.2 μM (0.975 μg/mL)，可用于癌症研究。
Exatecan mesylate (DX8951f) 是一种 DNA 拓扑异构酶 I (topoisomerase I) 抑制剂，IC50 值为 2.2 μM (0.975 μg/mL)，可用于癌症研究。|
Topoisomerase I 0.975 μg/mL (IC 50 ) |
Exatecan mesylate is a potent topoisomerase I inhibitor, with an IC 50 of 0.975 μg/mL. Exatecan mesylate (DX-8951f) significantly inhibits the proliferation of several cancer cell lines, with mean GI 50 s of 2.02 ng/mL, 2.92 ng/mL, 1.53 ng/mL, and 0.877 ng/mL for breast cancer cells, colon cancer cells, stomach cancer cells and lung cancer cells, respectively. Exatecan mesylate (DX-8951f) displays cytotoxic activities against PC-6, PC-6/SN2-5 cells, with mean GI 50 s of 0.186 and 0.395 ng/mL, respctively. Exatecan mesylate (34 nM) stabilizes DNA-TopoI complexes in PC-6 and PC-6/SN2-5 cells.
Exatecan mesylate (DX-8951f, 3.325-50 mg/kg, i.v.) exhibits antitumor activities in the mice model bearing tumor cells, without toxic death. Exatecan mesylate (15, 25 mg/kg, i.v.) hightly inhibits MIA-PaCa, BxPC-3 primary tumor growth in the MIA-PaCa-2 early-stage model and early-stage model of BxPC-3. Exatecan mesylate (15, 25 mg/kg, i.v.) also significantly suppresses BxPC-3 lymphatic metastasis and completely eliminates lung metastasis in the BxPC-3 late-stage cancer model.